✨ Free AI Report
Akeso, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Akeso, Inc.
Research Preview

Akeso, Inc.: Business Overview, Financials & Competitive Analysis

Akeso is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of antibody drugs covering therapeutic areas of oncology, autoimmune and metabolic diseases. The company ...

Analyst-debate audio for Akeso, Inc.

AskCyborg analysts argue the bull and bear cases for Akeso, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Akeso, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Chinese antibody-drug leader with first-in-class candidates and superior clinical data poised to capture significant oncology...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Oncology Immunotherapy
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Akeso, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Akeso, Inc. Overview

Pro stress-test →

Akeso is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of antibody drugs covering therapeutic areas of oncology, autoimmune and metabolic diseases. The company has a pipeline of over 30 drugs, with 17 having entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF).

Strategic Profile

Pro stress-test →

Headquartered in Zhongshan, China, with a goal of becoming a global leader in innovative therapeutic antibodies, the company operates a diversified antibody drug pipeline covering over 20 drug development programs. Recent clinical data shows Akeso's immunotherapy drug has outperformed leading Western peers in studies, earning recognition as the 'DeepSeek moment' for China's drug industry.

Competitive Landscape

Pro stress-test →

Direct competitors in Chinese biotech include Innovent Biologics, RemeGen, Shanghai Junshi Biosciences, Shanghai Henlius Biotech, and others. Akeso differentiates through first-in-class bi-specific antibodies (PD-1/CTLA-4, PD-1/VEGF) with superior clinical efficacy compared to established Western competitors like Merck and BioNTech in oncology immunotherapy.

Industry Context

Akeso, Inc. operates in Biopharmaceutical/Oncology Immunotherapy.

Key facts

Founded: 2012 · Headquarters: Zhongshan, China · Employees: 3,529 · Market cap: $93.68B HKD

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Akeso, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Akeso, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KeytrudaPD-1 monoclonal antibody for oncology→TecentriqPD-L1 checkpoint inhibitor for solid tumors→BNT327Immuno-oncology asset in clinical development→Innovent Biologics PipelineChinese biotech competitor with multiple oncology candidates→

Compare Akeso, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Akeso, Inc. operates in Biopharmaceutical/Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Akeso, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Akeso, Inc. and its top competitor on Cyborg Score”
“What did Akeso, Inc. do this quarter?”
“Is Akeso, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Akeso, Inc. do?+
Akeso is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of antibody drugs covering therapeutic areas of oncology, autoimmune and metabolic diseases. The company ...
What is Akeso, Inc.'s Cyborg Score?+
Akeso, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Akeso, Inc.'s main competitors?+
Named competitors include Keytruda, Tecentriq, BNT327, Innovent Biologics Pipeline. The full competitive landscape is in the AskCyborg report.
How can I get the full Akeso, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Akeso, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Akeso, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score